APOE and central nervous system cancer: Recently, PS‐80 brings with new tool to address this issue through activating ApoE‐mediated transport pathway.21, 22, 23 However, PS‐80‐meadiated whole brain drug delivery unavoidably brings some risks for glioma patients and was invalid for these glioma patients with low ApoE expression or ApoE functional defects.